CHARLOTTE, N.C. – Alveolus, a developer of stent technology, has received Food and Drug Administration approval for a new product for use in treatment of malignant pulmonary obstructions.

The AERO Hybrid Tracheobronchial Stent System can be used to open an airway that is blocked by a tumor. The stent is designed to relieve difficulty in breathing and also to reduce the length of time a patient needs to be in a hospital.

Alveolus focuses on non-vascular stent technology.